New biomarker shows promise for pitch-side brain injury test
Researchers at the University of Birmingham have identified inflammatory biomarkers which indicate whether the brain has suffered injury.
List view / Grid view
Biomarkers are a naturally occurring molecule, gene, or characteristic by which a particular disease can be identified.
Researchers at the University of Birmingham have identified inflammatory biomarkers which indicate whether the brain has suffered injury.
A review of Keap1/Nrf2 modulation of ROS homeostasis, and its pivotal role in the pathogenesis of cancer, Type 2 diabetes mellitus & neurological disorders.
Included in this Screening In-Depth Focus: Phenotypic and target-based screening; Killing cancer cells using clinical drug resistance; Inflammatory biomarkers as a herbal anti-arthritic drug discovery tool...
Since the sequence of the human genome was published some 20 years ago, omics strategies have enabled the generation of detailed molecular signatures of cancers and their subtypes.
Included in this issue: Technology convergence improves testing; Screening; Stem Cells; Targets; Mass Spectrometry; and Therapeutics in Alzheimer's disease...
Measuring a blood marker, copeptin, can successfully predict the risk of heart attacks in people with type-2 diabetes.
Study shows 'liquid biopsy' after abnormal mammogram and other imaging can help rule out breast cancer, reduce breast biopsy by up to 67% in women...
New research provides insights into why infection with Zika virus after birth generally causes only mild symptoms, whereas devastating foetal malformations can develop when infection occurs during pregnancy.
A highly sensitive method that can detect even the earlier stages of colorectal cancer has been developed by researchers in Japan.
Head trauma is a common injury, and according to several scientific studies, undiagnosed concussion may lead to devastating outcomes and a premature neurodegenerative condition.
Scientists have established a process for identifying biomarkers for the diagnosis of different types of cancer.
The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK.
Drug developers sometimes think of imaging as an emerging discipline. But John Waterton, Paul Hockings, Juliana Maynard and Caleb Roberts explain how imaging biomarkers are transforming drug development. Francesco Gatto and Jens Nielsen, from the Chalmers University of Technology in Sweden, discuss moving towards systems biomarkers for cancer diagnosis...
BenevolentBio's CMO, Dr Patrick Keohane, says the industry is on the cusp of an artificial intelligence (AI) revolution...
Included in this issue: Importance of building patient trust; Vaccines & Immunology; Oncology; Assays; Biomarkers; and Antibodies...